Q-omics provides the consensus-scored CAPN12 profile across patient tissues and cancer cell-line models. CAPN12 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CAPN12 is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, CAPN12 RNA expression shows 17,753 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KIRC, and UVM as cancer lineages where CAPN12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CAPN12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CAPN12 survival associations across molecular data types. CAPN12 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CAPN12 RNA expression–survival associations across cancer types. High CAPN12 expression shows unfavorable associations in ACC, COAD, LGG, UVM and CESC, but favorable associations in LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CAPN12 RNA expression.
This table summarizes CAPN12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CAPN12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CAPN12 shows lower tumor expression in KICH and higher tumor expression in KIRC, HNSC, COAD, BLCA and LUAD. The KIRC box plot shows higher CAPN12 RNA expression in tumor versus normal tissue (log2 FC = +2.096, t-test p < 0.001).
This table shows molecular features associated with CAPN12 in patient tissues and cancer cell lines. In patient samples, CAPN12 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CAPN12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and KIDNEY.
